Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 520

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials

Open access
Galipeau, Jacques, Krampera, Mauro, Barrett, John, Dazzi, Francesco, Deans, Robert J., DeBruijn, Joost, Dominici, Massimo, Fibbe, Willem E., Gee, Adrian P., Gimble, Jeffery M., Hematti, Peiman, Koh, Mickey B.C., LeBlanc, Katarina, Martin, Ivan, McNiece, Ian K., Mendicino, Michael, Oh, Steve, Ortiz, Luis, Phinney, Donald G., Planat, Valerie, Shi, Yufang, Stroncek, David F., Viswanathan, Sowmya, Weiss, Daniel J., Sensebe, Luc·2016·Cytotherapy

Abstract

Mesenchymal stromal cells (MSCs) as a pharmaceutical for ailments characterized by pathogenic autoimmune, alloimmune and inflammatory processes now cover the spectrum of early- to late-phase clinical trials in both industry and academic sponsored studies. There is a broad consensus that despite different tissue sourcing and varied culture expansion protocols, human MSC-like cell products likely share fundamental mechanisms of action mediating their anti-inflammatory and tissue repair functionalities. Identification of functional markers of potency and reduction to practice of standardized, easily deployable methods of measurements of such would benefit the field. This would satisfy both mechanistic research as well as development of release potency assays to meet Regulatory Authority requirements for conduct of advanced clinical studies and their eventual registration. In response to this unmet need, the International Society for Cellular Therapy (ISCT) addressed the issue at an international workshop in May 2015 as part of the 21st ISCT annual meeting in Las Vegas. The scope of the workshop was focused on discussing potency assays germane to immunomodulation by MSC-like products in clinical indications targeting immune disorders. We here provide consensus perspective arising from this forum. We propose that focused analysis of selected MSC markers robustly deployed by in vitro licensing and metricized with a matrix of assays should be responsive to requirements from Regulatory Authorities. Workshop participants identified three preferred analytic methods that could inform a matrix assay approach: quantitative RNA analysis of selected gene products; flow cytometry analysis of functionally relevant surface markers and protein-based assay of secretome. We also advocate that potency assays acceptable to the Regulatory Authorities be rendered publicly accessible in an "open-access" manner, such as through publication or database collection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jcyt.2015.11.008

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 520

Metadata

Authors
Galipeau, J., Krampera, M., Barrett, J., Dazzi, F., Deans, R. J., DeBruijn, J., Dominici, M., Fibbe, W. E., Gee, A. P., Gimble, J. M., Hematti, P., Koh, M. B. C., LeBlanc, K., Martin, I., McNiece, I. K., Mendicino, M., Oh, S., Ortiz, L., Phinney, D. G., Planat, V., Shi, Y., Stroncek, D. F., Viswanathan, S., Weiss, D. J., & Sensebe, L.
Venue
Cytotherapy
Publisher
Elsevier BV
Published
2016-02
Volume
18
Issue
2
Pages
151-159
ISSN
1465-3249 (ISSN-L)
OpenAlex
W2201248084
Cited by
520
References
3
FWCI
18.59
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. https://app.cochat.ai/papers/10.1016/j.jcyt.2015.11.008
The paper
Galipeau, J., Krampera, M., Barrett, J., Dazzi, F., Deans, R. J., DeBruijn, J., Dominici, M., Fibbe, W. E., Gee, A. P., Gimble, J. M., Hematti, P., Koh, M. B. C., LeBlanc, K., Martin, I., McNiece, I. K., Mendicino, M., Oh, S., Ortiz, L., Phinney, D. G., . . . Sensebe, L. (2016). International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. https://doi.org/10.1016/j.jcyt.2015.11.008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.